Company Filing History:
Years Active: 2022-2023
Title: Yusuke Totoki: Innovator in Antitumor Antibody Development
Introduction
Yusuke Totoki is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of novel therapeutic antibodies. With a total of 2 patents, his work focuses on innovative solutions for cancer treatment.
Latest Patents
Yusuke Totoki's latest patents revolve around the Anti-CD147 antibody. The primary objective of this invention is to provide a novel anti-CD147 antibody that exhibits potent antitumor efficacy while ensuring excellent safety. This invention also includes a pharmaceutical product that comprises such an antibody. Furthermore, it outlines a method for treating tumors using the antibody or the pharmaceutical product. The present invention highlights a CD147-specific antibody that activates CD147 and demonstrates high antitumor efficacy. Notably, this anti-CD147 antibody exhibits high antitumor efficacy independent of effector functions. Additionally, the invention provides a pharmaceutical composition that includes this anti-CD147 antibody, along with methods for treating tumors using the antibody and/or pharmaceutical composition.
Career Highlights
Yusuke Totoki is currently associated with Daiichi Sankyo Company, Limited, where he continues to advance his research and development efforts in the field of oncology. His work is instrumental in paving the way for new therapeutic options for patients battling cancer.
Collaborations
Yusuke has collaborated with notable colleagues, including Keisuke Fukuchi and Kayoko Nanai, to further enhance the impact of his research and innovations.
Conclusion
Yusuke Totoki's contributions to the development of the Anti-CD147 antibody represent a significant advancement in cancer treatment. His innovative approach and dedication to research continue to inspire progress in the field of biotechnology.